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Background: The importance of ERBB2/NEU/HER2 in the response of breast tumours to the heat shock protein 90
(HSP90) inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG; tanespimycin) has been demonstrated in the
clinic. ERBB2 is an oncoprotein client that is highly dependent on HSP90. This and other oncogenic client proteins
(e.g. B-RAF, C-RAF, ALK and CDK4) are depleted by 17-AAG in both animal tumours and patients. Here we investigate by
Magnetic Resonance Spectroscopy (MRS) the metabolic response of 17-AAG in spontaneous, NEU/HER2 driven
mammary tumours in transgenic MMTV-NEU-NT mice and in cells isolated and cultured from these tumours.
Methods: Mammary tumours were monitored by 31P MRS in vivo and in tumour extracts, comparing control and
17-AAG treated mice. A cell line derived from NEU/HER2 mammary tumours was also cultured and the effect of
17-AAG was measured by 31P MRS in cell extracts. Molecular biomarkers were assessed by immunoblotting in extracts
from cells and tumours. For comparison of tumour volume, metabolite concentrations and Western blot band
intensities, two-tailed unpaired t-tests were used.
Results: The NEU/HER2 mammary tumours were very sensitive to 17-AAG and responded in a dose-dependent
manner to 3 daily doses of 20, 40 and 80mg/kg of 17-AAG, all of which caused significant regression. At the higher
doses, 31P MRS of tumour extracts showed significant decreases in phosphocholine (PC) and phosphoethanolamine (PE)
whereas no significant changes were seen at the 20mg/kg dose. Extracts of isolated cells cultured from the mammary
carcinomas showed a significant decrease in viable cell number and total PME after 17-AAG treatment. Western blots
confirmed the expected action of 17-AAG in inducing HSP72 and significantly depleting HSP90 client proteins,
including NEU/HER2 both in tumours and in isolated cells.
Conclusions: The data demonstrate the high degree of sensitivity of this clinically relevant NEU/HER2-driven tumour
model to HSP90 inhibition by 17-AAG, consistent with the clinical data, and suggest that the metabolic signature of
choline phospholipids obtained by MRS could be useful both as a preclinical and clinical tool for investigating surrogate
markers of response to treatment.
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The novel anticancer drug 17-allylamino-17-demethoxy-
geldanamycin (17-AAG; tanespimycin), which inhibits the
molecular chaperone HSP90, has shown activity against
breast cancer in the clinic [1-3]. Regressions were seen
only in patients with metastatic breast cancer that was
positive for ERBB2/HER2, a very sensitive oncoprotein cli-
ent of HSP90. The ERBB2 receptor tyrosine kinase, a
member of the epidermal growth factor receptor (EGFR)
family, is overexpressed in 20-30% of primary human
breast cancers, and expression correlates with poor patient
outcome [4]. ERBB2/HER2 is a target for both antibody-
based therapy (as with trastuzumab) and tyrosine kinase-
based inhibitors (as with lapatinib), but resistance is seen
in the clinic [5]. ERBB2/HER2 is one of the most sensitive
client proteins of HSP90 [6,7], and 17-AAG has been
shown to cause depletion of ERBB2/HER2 leading to sig-
nificant growth inhibition in ERBB2/HER2 overexpressing
breast cancer cells and tumour xenografts [8], and more
importantly to cause regression in trastuzumab-refractory
ERBB2/HER2 positive breast cancer patients [1-3]. Data
from Phase 2 trials have recently confirmed this impres-
sive anti-tumour activity of 17-AAG and validated HSP90
as a therapeutic target for ERBB2/HER2-driven breast
cancer [2].
17-AAG, a derivative of the naturally-occurring ansamy-
cin antibiotic geldanamycin, is known to bind specifically
to the ATP site in the NH2-terminal domain of the mo-
lecular chaperone HSP90 and inhibit its function [7,9]. As
well as ERBB2, HSP90 is required for the correct conform-
ation and function of many other oncogenic client pro-
teins, including CDK4, C-RAF, B-RAF, AKT, MET, ALK,
EGFR and p53 [10,11].
Several mutant oncoproteins are more dependent than
their wild-type forms on HSP90 but ERBB2 is the most
sensitive HSP90-dependent client protein identified to date
[11,12]. Tumour cells contain HSP90 complexes in a more
highly activated, high affinity conformation compared to
normal cells, and it has been proposed that this might con-
tribute to malignant progression [13]. HSP90 is therefore a
key therapeutic target, since a drug that simultaneously
inhibits several oncogenic signaling pathways is likely to be
particularly effective [7,11,12,14]. Recent clinical experience
indicates that HSP90 inhibitors are showing therapeutic ac-
tivity in settings where they deplete sensitive HSP90 clients
in tumour types that are addicted to those clients, with
ERBB2-positive, trastuzumab-refractory breast cancer pro-
viding the best example [2,3]. Clinical development of
HSP90 inhibitors is focusing heavily on these tumours and
additional studies in mechanistically relevant preclinical
models are warranted to support and inform the ongoing
clinical work.
The development of transgenic mouse models that re-
capitulate the initial events of ERBB2-induced mammarytumourigenesis has played a key role in understanding
the molecular basis of ERBB2-driven tumours [15].
NEU/HER2 is the rat homolog of human ERBB2 and in
one transgenic mouse model, MMTV-NEU-NT, that
expresses the activated mutant form of NEU under the
transcriptional control of the MMTV promoter, the
mice develop spontaneous tumours in the mammary
gland [16]. This tumour model is particularly suited to
studying the effects of 17-AAG since the tumours that
arise are driven by the activated form of the NEU/HER2
oncogene and are addicted to it, just as ERBB2 amplified
breast cancers in the clinic are driven by and addicted to
the amplified ERBB2. The action of 17-AAG on HSP90
promotes the degradation of client proteins through the
ubiquitin-proteasome pathway, and such a pleiotropic
mechanism may induce complex metabolic effects that
may vary from one tumour to another. In the discovery
and in early clinical trials of HSP90 inhibitors, it will
therefore be important to develop non-invasive monitor-
ing methods that can distinguish these responses. Such
methods could then be used in the clinic to select
tumours that are likely to respond to treatment, with
advantages over more invasive techniques [17-19].
Magnetic resonance spectroscopy (MRS) can be used
non-invasively to study the biochemistry and physiology of
tumours in vivo, and also ex vivo on extracts of either
tumours or cells. 31P MRS has been used to monitor
growth and response to therapy both in animal tumour
models and in patients [20-24]. Biomarkers for tissue bio-
energetics, such as nucleotide triphosphate (NTP), inor-
ganic phosphate (Pi), and intracellular pH (pHi), as well as
various phosphorus-containing phospholipid metabolites
are readily observed with 31P-MRS. The phospholipid
metabolites that provide information on membrane
metabolism are the phosphomonoesters (PMEs) phospho-
choline (PC) and phosphoethanolamine (PE), which are
precursors of the phosphatidylcholine and phosphatidy-
lethanolamine in biological membranes, and the phos-
phodiesters (PDEs) glycerophosphocholine (GPC) and
glycerophosphoethanolamine (GPE), which are break-
down products of phosphatidylcholine and phospha-
tidylethanolamine. The pharmacodynamic actions of
many anticancer drugs have been studied, and charac-
teristic 31P MRS signatures established (for a review see
[25]). Since MRS changes induced by 17-AAG occur in
parallel with the expected molecular marker changes,
the MRS signatures have the potential to provide surro-
gate markers of treatment response [26-28]. We there-
fore set out to look at the MRS signature of the action
of 17-AAG in spontaneous, mammary tumours in
transgenic MMTV-NEU-NT mice where the tumors
that arise are driven by the activated form of the NEU/
HER2 oncogene and are addicted to it, similar to ERBB2
amplified breast cancer in the clinic.
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Materials
17-AAG for the in vivo and in vitro study was either pro-
vided (dissolved in DMSO at 25mg/mL) by Dr. P. Ivy at
the National Cancer Institute (Bethesda, MD) or purchased
(powder form) from Alexus Biochemicals (Switzerland)
and dissolved in DMSO at 25mg/mL. Dilutions to 2.5mg/
mL were made in a vehicle of egg phospholipid sup-
plied by Dr. P. Ivy. Dulbecco’s Modified Eagle Medium
(DMEM), penicillin, and streptomycin were purchased
from Life Technologies (Paisley, UK) and fetal calf serum
(FCS) from PAA labs Ltd. (Somerset, UK). Hypnorm was
purchased from Jansen Pharmaceuticals (Buckinghamshire,
UK), and Hypnovel was purchased from Roche (Welwyn
Garden City, UK). Perchloric acid (PCA) and potassium
hydroxide were purchased from Merck (Poole, UK).
Sodium 3-trimethylsilyl-2,2,3,3-tetra-deuteropropionate
(TSP) was purchased from Goss Scientific Instruments
Ltd, UK. All other chemicals were purchased from
Sigma (Poole, UK).
MMTV-NEU-NT tumour model
Female transgenic mice expressing the mutant activated
form of rat NEU (NEU-NT) under transcriptional con-
trol of the MMTV promoter (MMTV-NEU-NT mice)
were purchased from Charles River, UK. The mating
strain is the FVB/N mouse and multiple tumours involv-
ing the entire mammary epithelium arise synchronously
in the mammary gland area [16] between 18-20 weeks of
age in 35-50% of the mice.
Mice were maintained under strict inbreeding condi-
tions; health was monitored every 3 months and the
presence of the Neu transgene was routinely checked by
PCR on tail DNA. Animals were anesthetized with 8mL/
kg of a Hypnorm: Hypnovel: water (1:1:2) mixture. All
experiments were performed in accordance with the UK
Home Office Animals Scientific Procedures Act 1986
and national UK Coordinating Committee on Cancer
Research’s (UKCCCR) guidelines [29]. All measures were
taken to minimize any pain or discomfort to the
animals.
Tumour volume was calculated using the formula (π/6)
(d1d2d3) where d1, d2 and d3 are the three orthogonal
diameters measured by callipers to derive an ellipsoidal
volume.
Several cohorts of mice were used: of the treated
cohorts, one received 20mg/kg 17-AAG i.p., a second
received 40mg/kg and a third received 80mg/kg, once a
day for 3 days. The fourth control cohort received ve-
hicle (egg phospholipid in 10% DMSO), once a day for 3
days. In vivo MRS was performed on day 0 and day 4,
and tumours were freeze-clamped on day 4. Western
blot analysis was performed on part of the tumour
tissue, and 31P and 1H MRS were performed on acidextracts of tumour tissue. In a fifth cohort, as part of a
regrowth study, the mice received 40mg/kg 17-AAG
once a day for 3 days and the tumours were monitored
up to 14 days after the end of treatment.
In vivo MRS
In vivo magnetic resonance experiments were performed
on a Varian Unity Inova 4.7T spectrometer. During the
MR experiments, all animals were covered with a warm
water blanket and core temperature maintained at 37°C.
For 31P MRS, the volume of interest selected from a
1H image included as much of the tumour as possible
and avoided the underlying body wall. ISIS (image-
selected in vivo spectroscopy) [30] localized spectra of
tumours were acquired using a 10mm, two-turn surface
coil, TR of 3s and 240 acquisitions. Spectra were
acquired prior to treatment and at day 4 in the cohorts
that received 3 doses, at 24 hr in the single dose cohort
and at days 4, 8, 11 and 18 in the regrowth cohort. Spec-
tra were quantitated using VARPRO, a time-domain
non-linear least squares method [31]. The data were fit-
ted assuming contributions from phosphomonoesters
(PME), phosphodiesters (PDE), inorganic phosphate (Pi),
phosphocreatine (PCr), and the α-, β- and γ-nucleoside
triphosphate (NTP) resonances.
High resolution 1H and 31P MRS of tumour extracts
Part of the freeze-clamped tumour was extracted with 4
volumes of 6% PCA. The neutralized extracts were freeze-
dried, reconstituted in deuterium oxide and placed in
5mm NMR tubes. MR spectra were acquired at room
temperature on a 500MHz Bruker spectrometer (Bruker
Biospin, Coventry, UK).
For 1H MRS, the water resonance was suppressed by
using gated irradiation centered on the water frequency.
TSP (50ul, 5mM) was used for chemical shift calibration
and quantitation.
For 31P MRS, metal ions were chelated by addition of
EDTA (50ul, 60mM) and methylene diphosphonic acid
(MDP, 50ul, 5mM) was added to each sample for chemical
shift calibration and quantitation.
Metabolite concentrations were determined by peak in-
tegration, normalized to the peak integral of the respective
internal standard (TSP for 1H and MDP for 31P MRS).
Cell culture and drug treatment
A cell line of ERBB2/HER2-induced mammary carcinoma
cells was established from a tumour mass excised from an
MMTV-NEU-NT mouse [15,16]. The tumour cells were
cultured in DMEM supplemented with 10% FCS, 100U/mL
penicillin and 100 μg/mL streptomycin at 37°C in 5% CO2.
Cell growth inhibition (96-hours) for these tumour cells,
with seeding density of 1 × 103 in 200 μL using 96
well plates, was measured by sulforhodamine B (SRB)
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at pharmacologically active concentrations corresponding
to 5 x GI50 (1.12 μM) for 24-hours at 37°C. The cells were
collected by scraping, and viability was checked by the try-
pan blue exclusion assay [26]. The effect of treatment on
viable cell number was monitored by counting the number
of attached cells in the treated flask and comparing that
with the number of attached cells in the control flask.
Cell cycle analysis
Cell cycle analysis of attached control and treated cells
was performed on cells (1 × 106) fixed in 70% ethanol,
treated with 100 μg/mL RNase A in citrate-buffered sa-
line for 30 minutes at 37°C and stained with 4 μg/mL
propidium iodide [33]. Samples were analysed on a BD
LSR II (San Jose, CA, USA) on a “low” flow rate and
excited using a 488 nm laser beam, fluorescent light col-
lected at 610/20 nm on a linear scale for the cell cycle
analysis. Concurrently data were collected at 660/20 nm
on a log scale to assess samples for endoreduplication.
The flow cytometry data were analyzed and quantified
using the WinMDI and Cylchred softwares (University
of Wales College of Medicine, Cardiff, UK).
High resolution 31P-MRS of cultured cell extracts
5x107 cells, approximately in log phase, were extracted
from cell culture as previously described [34,35]. The
freeze-dried extracts were resuspended in D2O with
10mM EDTA (pH 8.2).
1H-decoupled 31P-MRS spectra were acquired at room
temperature on a 500 MHz Bruker spectrometer (Bruker
Biospin, Coventry, UK) using a 30° flip angle, a 1s relax-
ation delay, spectral width of 100 ppm, and 32 K data
points. Metabolite contents were determined by integra-
tion, normalized relative to the peak integral of an in-
ternal reference of MDP (60 μL, 1 mM), and corrected
for signal intensity saturation and the number of cells
extracted per sample.
Western blot analysis
Standard Western blotting procedures were performed as
described previously [36]. Briefly, cells were trypsinized,
washed with PBS and lysed at 4°C in lysis buffer (Cell Sig-
nalling, Hertfordshire, UK) and protease inhibitor cocktail
(Roche diagnostics, Mannheim, Germany). Protein con-
centrations were determined by the BIO-RAD assay
method and bovine serum albumin as a standard. Anti-
body binding was identified with horseradish peroxidase-
labeled secondary antibodies combined with enhanced
chemiluminescence reagents (Amersham, Bucks, UK) and
autoradiography.
Freeze-clamped tumours were lysed in 1ml of lysis buffer
(0.1% Nonidet P-40, 50mM HEPES (pH 7.4), 250mM NaCl,
1mM phenylmethylsulfonyl fluoride, 10ug/ml aprotonin,20uM leupeptin, 1mM dithiothreitol, 1mM EDTA, 1mM
NaF, 10mM β-glycerophosphate and 0.1mM orthovana-
date), protein concentration determined by the BCA pro-
tein assay (Thermo Scientific Pierce) and Western blotting
procedures were followed as above.
Antibodies used were HSP72 (SPA 810; Stressgen,
Canada), B-RAF (SC5284; Santa Cruz Biotechnology,
Santa Cruz, CA, USA), C-RAF (SC133; Santa Cruz Bio-
technology, Santa Cruz, CA, USA), CDK4 (SC260; Santa
Cruz Biotechnology), p-NEU (2247; Cell Signaling Tech-
nology), NEU/HER2 (SC284; Santa Cruz Biotechnology),
and also glyceraldehyde-3-phosphate dehydrogenase
(GAPDH; MAB374; Chemicon, Hampshire, UK) as a
loading control.
Images of the blots of solid tumor and cell extracts
were scanned on a ImageScanner III (GE HealthCare)
using Labscan software, and bands were quantified by
densitometry using the ImageQuant TL software.
Statistical analysis
The tumour cell data, solid tumour and tumour extract
data are presented as the mean ± SEM, n = 3-6. For
comparison of metabolite concentrations and tumour
volumes, two-tailed unpaired t tests were used, and a
p value of <0.05 was considered to be statistically
significant.
Results
Dose-dependent effects of 17-AAG on tumour volume
The MMTV-NEU-NT mice developed multiple tumours
associated with the mammary gland between 18-20
weeks of age. The tumour volumes at day 0, the day pre-
ceding the first dose of treatment, were 0.59 ± 0.08cm3
(n = 11), 0.67 ± 0.07cm3 (n = 11), 0.67 ± 0.08cm3 (n = 10),
and 0.61 ± 0.12cm3 (n = 6) for the control 20, 40 and
80mg/kg cohorts respectively.
Tumours in the control mice (treated with vehicle
only) had a doubling time of 12 ± 2 days (n = 6) and grew
to 128 ± 6% of pre-treatment volume after 4 days, while
the tumours treated with 3 daily doses of 17-AAG at
20mg/kg, 40mg/kg and 80mg/kg regressed to 88 ± 3 %
(p< 0.003), 67 ± 6% (p< 0.003) and 42 ± 7%
(p< 0.0005) respectively (compared with pre-treatment
volume on day 0) by day 4. When the tumour volumes
at day 4 post-treatment were compared to untreated
tumour volumes at day 4, there were highly significant
differences (p< 0.0002) at all doses (Table 1). There
were significant differences in tumour volumes between
the 40mg and 80mg/kg cohorts (p< 0.03) and bet-
ween the 40mg and 20mg/kg cohort (p< 0.02). These
results show that the NEU-NT tumours are very sensi-
tive to treatment with 17-AAG and demonstrate dose-
dependence of the therapeutic effect. The responsiveness
is consistent with the results observed in a clinical study
Table 1 Effect of 17-AAG on tumour volume
Tumour
volume
(% of day 0)










Control 128.4 ± 5.9 (11) 0.0007
17-AAG
(20mg/kg)
88.5 ± 2.9 (11) 0.003 68.9% <0.0001
17-AAG
(40mg/kg)
67.0 ± 3.6 (10) <0.0001 52.2% <0.0001
17-AAG
(80mg/kg)
42.1 ± 7 (6) 0.0004 32.8% <0.0001
Effect of 3 daily doses of 17-AAG (20mg/kg, 40mg/kg, 80mg/kg) or vehicle
only (control) on tumour volume in MMTV-NEU-NT transgenic mice. Tumour
volume expressed as a % of day 0 (column 2), p values: day 4 vs day 0.
Tumour volume also expressed as a % of control cohort at day 4 (column 4), p
values: treated day 4 vs control day 4. Mean tumour volume at day 0 of the 4
cohorts was 0.59 ± 0.08 cm3 (control), 0.67 ± 0.07 cm3 (20mg/kg), 0.67 ± 0.08
cm3 (40mg/kg) and 0.61 ± 0.12 cm3 (80mg/kg). Data are presented as the
mean ± SEM.
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cancer using 17-AAG in combination with trastuzumab
[1,2].
In one cohort of mice (n = 4), where the animals were
not sacrificed immediately after treatment (3 daily doses
of 40 mg/kg 17-AAG), the tumours subsequently regrew
at the original rate after the end of treatment (Figure 1).NEU/HER2
Control 17-AAG (40mg/kg)
Effects of 17-AAG on molecular biomarkers in MMTV-
NEU-NT tumours
HSP72 induction is known to be a sensitive indicator of
HSP90 inhibition and is used alongside client protein
depletion as a validated biomarker signature of HSP90
inhibition [37]. Western blots for HSP72, NEU/HER2,Figure 1 Effect of 17-AAG on tumour volume of MMTV-NEU-NT
tumours in transgenic mice: Mice were treated with 17-AAG
(40mg/kg, days 1-3) with subsequent regrowth (■), vehicle
treated controls (□). Tumour volume is expressed as % of volume
at day 0. Data are presented as mean ± SEM (n = 4).C-RAF and CDK4 were carried out on tumours from a
cohort of 3 control mice and 3 mice treated with 40mg/kg
of 17-AAG for 3 days, where tumours were excised 24
hours after the last dose. The expected mechanism-based
increase in HSP72 expression [37,38] was observed in all 3
treated tumours, and a decrease in the expression of NEU/
HER2, C-RAF and CDK4 was seen in 2 out of 3 tumours
(Figure 2). The intensity of each protein band was deter-
mined relative to GAPDH. The mean normalized band
intensity of NEU/HER2 decreased from 3.64±0.06 to
1.86±0.37 (p =0.009); C-RAF decreased from 3.01±0.04
to 1.47±0.29 (p=0.006); HSP72 increased from zero to
3.12±0.25 (p =0.0002); and CDK4 decreased from
2.1±0.07 to 1.22± 0.1, (p= 0.002). Extracts of tumours
from the 20mg/kg cohort, taken 8hrs after the third dose,
also showed consistent increases in HSP72 in all tumours
and decreases in the expression of NEU/HER2 and
phospho-NEU/HER2, C-RAF and CDK4, in 4 out of 6
tumours The mean band intensity, relative to GAPDH, of
NEU/HER2 decreased from 1.09±0.02 to 0.67±0.14
(p= 0.03); phospho-NEU/HER2 decreased from 0.58±0.11
to 0.12±0.11 (p=0.03); C-RAF decreased from 0.21±0.05
to 0.04 ±0.02 (p= 0.04); CDK4 decreased from 0.23±0.04
to 0.05±0.03 (p= 0.02); and HSP72 increased from
zero (undetectable) to 0.35 ± 0.1 (p = 0.02). Data are




Figure 2 Effect of 17-AAG on HSP90 biomarkers in MMTV-NEU-NT
tumours : Western blots are shown for NEU/HER2, C-RAF, heat
shock protein HSP72 and CDK4 expression in MMTV-NEU-NT
tumours following treatment in mice with vehicle control (lanes
1-3), and 17-AAG, 40mg/kg, days 1-3 (lanes 4-6). Tumours were
excised 24 hours after the last dose. GAPDH was used as a loading
control.
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show that 17-AAG caused a significant depletion of HSP90
client proteins, including NEU/HER2 in the MMTV-NEU-
NT tumour model at 20mg/kg and 40mg/kg.
Effects of 17-AAG on PC and PE levels in MMTV-NEU-NT
tumours measured by high resolution 1H and 31P MRS in
tumour extracts
31P MRS of extracts allows better resolution of the
signals than spectra acquired from in vivo tissue. Spectra
of extracts of tumours from mice that had received 3
daily doses of 17-AAG were acquired, and individual
phospholipid metabolites, i.e. PC, PE, GPC and GPE,
were observed. Tumours from mice treated with 3 doses
of 80mg/kg 17-AAG showed decreases in PE (p = 0.01),
PC (p = 0.06) and [PE + PC] (p = 0.001). At the 40mg/kg
dose the sum of [PE + PC] was significantly lower
(Figure 3) when compared with vehicle-treated controls
(p = 0.05). GPC and GPE levels were not significantly dif-
ferent at any of the 17-AAG dose levels when compared
with vehicle-treated controls (Figure 3). 1H MRS of the
extracts confirmed a significant decrease in PC in a co-
hort of tumours 24 hrs after treatment with 40mg/kg
17-AAG, but no other significant changes were observed
(data not shown).
Effects of 17-AAG on PME levels in MMTV-NEU-NT
tumours in vivo measured by 31P MRS
The metabolic response signature was also assessed as a
potential non-invasive in vivo biomarker of HSP90 in-
hibition [26] pre and post 3 days of 40mg/kg 17-AAG
treatment (see Figure 4). However, it was technicallyFigure 3 Effect of 17-AAG on phospholipid related metabolites and P
of 17-AAG (20, 40, 80 mg/kg) or vehicle only (control) and tumours s
n= 3 to 6, **p< 0.05, *p = 0.06 when compared to controls. Phosphoethan
glycerophosphoethanolamine (GPE), glycerophosphocholine (GPC).difficult to obtain spectra with a good signal to noise ratio
at the 80mg/kg dose due to the marked tumour regression
caused by the treatment (Table 1). This technical difficulty
has been noted in other MRS experiments in drug-
sensitive, rapidly regressing tumours [39]. No significant
changes were noted in PME/Total P, PME/NTP, NTP/Pi
ratios or intracellular pH in tumours pre- and post 17-
AAG treatment at either the 20mg/kg or 40mg/kg dose
(for 3 days) nor were there any significant changes in these
ratios in the vehicle-treated controls.
Effects of 17-AAG-treatment in cultured cells isolated
from MMTV-NEU-NT tumours
The effects of 17-AAG on the MMTV-NEU-NT tumour
extracts measured by 31P MRS were opposite to those
seen previously in HT29 human colon tumours [26];
significant decreases (p ≤ 0.05) in the phospholipid
metabolites PC and PE were observed in the MMTV-
NEU-NT tumours, in contrast to significant increases in
PC and PE (p ≤ 0.05) that had previously been seen in
HT29 colon tumours. However, significant regression
(p< 0.005) was seen at the 80, 40 and 20mg/kg doses in
the MMTV-NEU-NT tumours compared to the tumour
stasis that had previously been observed in the HT29
colon tumours, even at 80mg/kg. To investigate whether
these differences were characteristic of the MMTV-
NEU-NT tumours at the cellular level, we isolated and
cultured cells from the MMTV-NEU-NT tumours.
These cultured cells were then treated for 24 hours with
17-AAG at pharmacologically active concentrations cor-
responding to 5 x GI50 (1.12 μM) as defined using the
96 hours SRB assay. The number of 17-AAG treatedi by 31P MRS in extracts of MMTV-NEU-NT tumors: 3 daily doses
ampled at 24 hr post 3rd dose. Data are expressed as mean ± SEM.,
olamine (PE), phosphocholine (PC), inorganic phosphate (Pi),
A)  Pre 17-AAG treatment






15 10 5 0 -5 -10 -15 -20 -25 ppm
15 10 5 0 5 10 15 -20 -25 ppm
Figure 4 Effect of 17-AAG on in vivo 31P MR spectra of MMTV-NEU-NT tumours in transgenic mice: 3 daily doses of 40mg/kg 17-AAG:
A) pre-treatment with 17-AAG, B) 24 hrs after 3rd dose of 17-AAG.
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nificant reduction to 65.6 ± 6.1% (n = 6, P< 0.004), con-
sistent with decreased proliferation.
The MMTV-NEU-NT tumour cell line continued to
overexpress NEU/HER2 in cell culture and this expres-
sion was largely abolished by 17-AAG treatment, as
shown by western blotting (Figure 5A). The mean nor-
malized band intensity of NEU/HER2 decreased from
0.34 ± 0.04 to 0.05 ± 0.005 (p< 0.001). There were also
significant decreases in the normalized band intensity
of C-RAF, from 0.53 ± 0.11 to 0.21 ± 0.07 (p< 0.05), and
of cyclin D1, from 1.21 ± 0.1 to 0.85 ± 0.04 (p< 0.03).
Normalized intensity changes of B-RAF (1.96 ± 0.16 to
1.84 ± 0.12) and CDK4 (0.88 ± 0.1 to 0.79 ± 0.05) were
not significant. Treatment with 17-AAG also induced
HSP72 expression, the normalized band intensity of which
increased from 0.35±0.04 to 0.97± 0.05 (p< 0.0001).
Quantitation of band intensity is expressed relative to
GAPDH, mean± sem, n=5 (Figure 5A). These results pro-
vide molecular evidence that HSP90 was inhibited in the
17-AAG-treated cultured mammary tumour cells, includ-
ing marked depletion of NEU/HER2.
To further characterize the cellular effects of 17-AAG on
cultured MMTV-NEU-NT mammary tumour cells, cell
cycle distribution following 17-AAG treatment was deter-
mined by flow cytometry on the attached cell population.Exposure to 17-AAG induced a significant accumulation
in the G1 phase population from 50.9 ± 1.4% to 72.2 ± 0.8%
(n=6, p< 0.0001) and a decrease in the S phase popula-
tion from 40.3 ± 0.8% to 19.0± 0.9% (p< 0.0000001).
Effects of 17-AAG on phospholipid metabolites in extracts
of cultured cells isolated from MMTV-NEU-NT tumours
measured by high resolution 31P MRS
31P-MR spectra of extracts of control and 17-AAG-treated
(24hrs) mammary carcinoma cells cultured from MMTV-
NEU-NT mouse tumours are shown in Figure 5B.
Detailed analysis of the spectra demonstrated that 17-
AAG treatment led to a statistically significant decrease in
PME (76.8 ± 4.6%, p = 0.006). Of the signal contributing to
the total PME, the largest proportion (83%) came from PC
which also showed a significant decrease (66.7 ± 6.3%,
P = 0.005). However, a small but significant increase was
seen in the PE contribution (132.8± 11.3%, P< 0.05). GPE
(200.8± 46.6%) and GPC (204.4± 57.2%) both showed
increases but did not reach significance (p= 0.11 and 0.16
respectively) (Figure 5C). The ratio of PC/GPC also
showed a significant decrease (46.7 ± 10.9%, p< 0.01).
Discussion
The transgenic MMTV-NEU-NT mouse is a suitable
and relevant model for ERBB2-driven human breast
A) B)
C)
Figure 5 Effect of 17-AAG on cultured cells isolated from a MMTV-NEU-NT solid tumour. Cells treated for 24hr at 37°C with vehicle
(control) or 1.12μM 17-AAG. A) Western blots of NEU/HER2, B-RAF, C-RAF, HSP72, CDK4 and cyclin D1 in vehicle treated (lanes 1,3,5) and
17-AAG treated (lanes 2,4,6) cells. Intensity of bands were quantitated relative to GAPDH, (n = 5). B) 31P MR spectra of cell extracts from control
cells (bottom), or cells following 17-AAG treatment (top). Peak assignments are: phosphoethanolamine (PE), phosphocholine (PC), inorganic
phosphate (Pi), glycerophosphoethanolamine (GPE), glycerophosphocholine (GPC), phosphocreatine (PCr) and nucleotide triphosphate (α-, β-, γ-
NTP). Results were confirmed in six separate experiments, and representative spectra are shown. C) Percentage changes (relative to control) in
cell number, phosphoethanolamine (PE), phosphocholine (PC), glycerophosphoethanolamine (GPE), glycerophosphocholine (GPC),
phosphocreatine (PCr) and nucleotide triphosphate (β-NTP), phosphomonoesters (PME = PE + PC), PC/GPC, phosphodiesters (PDE = GPE + GPC)
and PDE/βNTP levels in MMTV-NEU-NT tumour cells following treatment with 17-AAG (1.12 μM) for 24h. Results are presented as the mean ±
SEM (error bars) of six separate experiments. *p≤ 0.05, **p< 0.01, two-tailed unpaired t test was used for all comparisons.
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vestigate effects of inhibition of the molecular chaperone
HSP90, both because ERBB2 is one of the client proteins
most sensitive to HSP90 inhibition and because of the
clinical activity seen with 17-AAG in ERBB2-positive,
trastuzumab-refractory breast cancer patients [1,2]. The
results reported in this paper show that the MMTV-
NEU-NT tumours are very sensitive to 17-AAG, con-
firming that NEU/HER2 is a prime target downstream of
17-AAG. Dose-dependent regression of the MMTV-NEU-NT tumours was seen at doses of 20, 40 and
80mg/kg (Table 1) whereas the drug has been found to
be cytostatic in human tumour xenografts, including the
HT29 colon tumour that we studied previously [26].
Tumour regrowth occurred soon after the treatment
ceased (Figure 1). This suggests that when treatment is
withdrawn, NEU/HER2 is able to recover its potent
oncogenic activity. Most importantly, the regressions
seen in the transgenic model recapitulated the regres-
sions seen in the ERBB2-positive breast cancer patients.
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AAG on the transgenic MMTV-NEU-NT (Figure 2)
tumours included the induction of the co-chaperone
HSP72 and depletion of client proteins NEU/HER2, C-
RAF and CDK4 (Figure 2). These results are consistent
with the well-established molecular signature of HSP90
inhibitors [7,10,11,37,38,40]. Similar molecular changes,
in addition to down-regulation of cyclin D1, were
observed in isolated, cultured NEU/HER2 mammary
cells following treatment with 17-AAG (Figure 5A).
No significant changes were seen in vivo by 31P MRS,
possibly because the tumours regressed so rapidly that the
signal/noise from the treated tumours was too low for
effects to be quantifiable. Studies performed on tumour
extracts at higher resolution ex vivo, however, did give sta-
tistically significant results. Increasing doses of 17-AAG
caused a progressive fall in the mean concentrations of PE
and PC measured in tumour extracts (Figure 3). Interest-
ingly, these were only significantly different at the higher
doses, when substantial tumour regression had taken place.
Extracts of cells cultured from the tumours also showed a
significant decrease in PC and total PME (PC + PE). How-
ever the PE component (17%) of the PME peak showed a
significant increase when expressed as a % of control cells.
PC, a cytosolic intermediate for the biosynthesis of phos-
phatidylcholine and a major phospholipid component of
human cellular membranes, can be a useful indicator of
tumour progression and therapeutic response [41]. In sev-
eral tumour types that have regressed after treatment, a de-
crease in PC has been seen [41], similar to the changes
observed in the extracts of both MMTV-NEU-NT tumours
in vivo and cells cultured from these tumours, in this study.
However in other cell and tumour types, an increase has
been seen (reviewed in [25-27]) and more recently, PC was
unchanged in a melanoma cell line [42] when treated with
17-AAG. The MRS metabolic response signature in solid
tumour extracts showed some differences to that observed
in the cultured mammary tumour cells - i.e. a decrease in
PE in solid tumours in contrast to an increase in PE in the
cultured cells. However, the tumours in vivo, unlike the iso-
lated cultured tumour cells, would of course contain many
other cells including stromal cells and macrophages, which
may well confound the metabolic signature. Although no
gross histological differences were seen between the treated
and untreated tumours, it is possible that factors associated
with regression (which also made it technically difficult to
obtain good MR spectra in vivo), contributed significantly
to the metabolic signature measured by MRS.
The fall in PE and PC in response to 17-AAG, observed
in solid tumour extracts in the present study (Figure 3)
should be considered in the context of the tumour- and
drug-dependent PE and PC responses that have been
obtained with 31P MRS in anticancer drug studies on
tumour models in rodents. A recent review [25] cites 31PMRS studies in which PE and/or PC increased in response
to chemotherapy with five anticancer drugs: 5-fluorouracil,
ifosfamide, LAQ824 and SAHA (histone deacetylase inhi-
bitors) and 17-AAG. In contrast, ten drugs induced falls in
PC and/or PE: cyclophosphamide, docetaxel, the choline
kinase inhibitor MN58b, the vascular disrupting agent
ZD6126, the HIF-1α inhibitor PX478, the PI3 kinase inhi-
bitors LY294002 and wortmannin, the MAPK inhibitor
U0126, and orlistate, a fatty acid synthase inhibitor. This
suggests that the PE and PC responses are drug-dependent
and perhaps also tumour model-dependent.
All the above studies, including our previous one on 17-
AAG [26] were performed on subcutaneously implanted
tumour models and/or on isolated cells. To our knowledge,
the present study is the first in which 31P MRS has been
used to monitor the effect of an HSP90 inhibitor on
spontaneous transgenic mouse tumours that arose in their
true tissue of origin, in this case the mammary gland. Spon-
taneous tumours in genetically-engineered animals have a
number of potential advantages over subcutaneously
implanted tumours for testing anticancer drugs [43]. In par-
ticular, their histology and vasculature in many cases more
closely resemble those of tumours in patients [44]. Since
MR spectra are derived from both the tumour cells and the
host stroma, that aspect of the model is important; indeed
the metabolic state of the tumour cells themselves is
strongly influenced by factors such as blood supply, which
is often less adequate in implanted tumours than in spon-
taneous tumours [45], and by the host inflammatory
response.
The 31P MRS response observed in human tumours
responding to chemotherapy in vivo in the clinic is often a
decrease in PE and PC (usually observed as a combined
PME peak). Negendank [41] performed a meta-analysis on
data from human tumours treated with chemotherapy
from eight studies and found that 26/34 tumours showed
a decreased PME peak, with 8 unchanged, whereas 4/7
non-responders showed increased PME peaks with 3 un-
changed [41]. It is interesting, therefore, that the spontan-
eous NEU-NT/HER2 overexpressing mammary tumours
studied here also showed decreased PE and PC in re-
sponse to 17-AAG. However, in view of the broad
spectrum and apparent drug-specificity of the PE and PC
results reported from previous studies with implanted
tumours, it will be necessary to wait for further results
from other anticancer drug studies on this tumour model
with respect to more detailed interpretation of the rela-
tionship between MRS signature and treatment response.
Conclusions
In this study we have determined the effects of 17-AAG in
a transgenic mouse tumour model that is driven by and
addicted to the activated form of the NEU/HER2 onco-
gene. It therefore represents a good model of ERBB2-
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tein is highly dependent on HSP90 for its activity and sta-
bility. Importantly, we show for the first time that the
transgenic mouse mammary tumours driven by NEU/
HER2 show significant regressions in response to 17-AAG
treatment. Importantly, this recapitulates the regressions
also seen in ERBB2-positive breast cancer patients. Regres-
sions were associated with a decrease in NEU/HER2 onco-
protein expression. The metabolic signature obtained by
31P MRS showed a decrease in choline phospholipid. This
finding was essentially similar between solid mammary
tumours treated in vivo and the isolated tumour cells trea-
ted in culture. The decrease in choline phospholipids is
consistent with a reduced malignant potential and suggests
a normalisation of the choline phospholipid metabolism.
The MRS changes observed in the choline phospholipid
metabolites are consistent with inhibition and depletion of
oncogenic signal transduction proteins, including NEU/
HER2, and with decreased cell proliferation and tumour
growth inhibition. Hence the observed MRS signature pro-
vides a basis for the potential use of MRS as a preclinical
and clinical biomarker tool for investigating the antitu-
mour activity of HSP90 inhibitors, particularly in the con-
text of NEU/HER2/ERBB2-driven breast cancer.Competing interest
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